INVESTORS

Driven by patient need, we have the potential to transform the treatment of NASH

NASDAQ: MDGL

 

INVESTORS

Driven by patient need, we have the potential to transform the treatment of NASH

NASDAQ: MDGL

A Company Focused on Improving Care for Patients with NASH.

Madrigal is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH). Our first therapy was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adults with NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) and is being studied in a Phase 3 trial for the treatment of NASH with compensated cirrhosis.